Anxiety
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Patients with PNES had higher self-reported anxiety and depression levels (GAD-7: p = 0.04, PHQ-9: p < 0.01; BDI-II: p < 0.01) but similar QOL to PWE (p = 0.78).
|
31759316 |
2020 |
Anxiety
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our study offers preliminary evidence for use of the PSWQ-A and GAD-7 for assessment of anxiety in a sample of low-income, predominantly African American participants.
|
30810345 |
2020 |
Anxiety
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To assess the levels of depression and anxiety, the PHQ-9 (The Patient Health Questionnaire), GAD-7 (Generalized Anxiety Disorder), SHS (Subjective Happiness Scale), and IPIP Big-5 questionnaires were used.
|
31117829 |
2020 |
Anxiety
|
0.100 |
Biomarker
|
disease |
BEFREE |
In a cross-sectional study, 23 patients with IPF were evaluated using Montreal Cognitive Assessment (MoCA), an instrument for detecting mild cognitive impairments and were screened for OSA through overnight cardiorespiratory polygraphy and for anxiety and depression with three specific scale (Generalized Anxiety Disorder 7-item scale: GAD-7; the Patient Health Questionnaire: PHQ-9; Hospital Anxiety and Depression Scale: HADS).
|
30707735 |
2019 |
Anxiety
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Hearing performance was assessed with Freiburg monosyllabic test and Oldenburg inventory (OI); the health-related quality of life was measured with Nijmegen Cochlear Implantation Questionnaire (NCIQ); depressive symptoms with General Depression Scale (ADS-L); stress with Perceived Stress Questionnaire (PSQ) and anxiety with General Anxiety Disorder-7 (GAD-7).
|
30870379 |
2019 |
Anxiety
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Data were collected by using a pre-developed questionnaire, consisting of socio-demographic information, comprehensive lifestyle information, and psychological health information including a nine-item scale, the Patient Health Questionnaire-9 (PHQ-9) for assessing the level of depression, and a 7-item scale, the Generalized Anxiety Disorder-7 (GAD-7) for assessing the level of anxiety.
|
31226611 |
2019 |
Anxiety
|
0.100 |
Biomarker
|
disease |
BEFREE |
There were no significant differences between SCP recipients and controls at 6 months postintervention on self-reported cancer and survivorship knowledge, physical functioning, satisfaction with information provision, or self-efficacy or at 12 months on anxiety, cancer-specific distress, depression, or satisfaction with follow-up care.
|
31653679 |
2019 |
Anxiety
|
0.100 |
Biomarker
|
disease |
BEFREE |
The 7-item Generalized Anxiety Disorder Scale (GAD-7) and the 9-item Patient Health Questionnaire (PHQ-9) were used to assess the anxiety and depressive symptoms of the mothers of the autistic children.
|
31393408 |
2019 |
Anxiety
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A total of 34% reported either a prior diagnosis of depression or scored 10 or greater on the PHQ-8, and 31% reported either a prior diagnosis of anxiety or scored 10 or greater on the GAD-7.
|
30637564 |
2019 |
Anxiety
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Emotional processing theory variables did not predict any anxiety outcomes at posttreatment or follow-up with one exception: Initial fear activation predicted less anxiety at follow-up among youth without GAD.
|
27355694 |
2019 |
Anxiety
|
0.100 |
Biomarker
|
disease |
BEFREE |
Item response theory-based linking methods were used to create crosswalk tables that convert scores on the GAD-7 to the TBI-QOL Anxiety metric and scores on the PHQ-9 to the TBI-QOL Depression metric.
|
31498233 |
2019 |
Anxiety
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Based on ICIQ-OAB scores, patients were dichotomized as having OAB versus LUTS-other, and GAD-7 scores categorized patients as having anxiety.
|
31302716 |
2019 |
Anxiety
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Of the 36 women who started iCBT, 26 completed all three lessons of treatment (76% adherence rate). iCBT produced moderate to large effect size reductions for anxiety on the GAD-7 (Hedges' g = 0.76) and psychological distress on the Kessler-10 (g = 0.88) that were superior to TAU.
|
30266030 |
2019 |
Anxiety
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Primary outcomes were (a) acceptability of the classes and retention rates and (b) changes in anxiety and depressive symptoms using Generalized Anxiety Disorder 7-item (GAD-7) and Patient Health Questionnaire 9-item (PHQ-9) scales.
|
31053070 |
2019 |
Anxiety
|
0.100 |
Biomarker
|
disease |
BEFREE |
The PHQ-9 and GAD-7 were determined to be potential screening tools to aid Chinese medical workers in recognizing depression and anxiety in nonpsychiatric departments.
|
30762438 |
2019 |
Anxiety
|
0.100 |
Biomarker
|
disease |
BEFREE |
Immunostaining in the basolateral amygdala (BLA) for GAD, a marker for GABA, at the end of the behavioral testing showed the late decrease in anxiety behavior was correlated with upregulation of inhibition.
|
30728770 |
2019 |
Anxiety
|
0.100 |
Biomarker
|
disease |
BEFREE |
Presence and frequency of depressive symptoms and anxiety were assessed by Patient Health Questionnaire (PHQ-9) and Generalized Anxiety Disorder Questionnaire (GAD-7).
|
30599337 |
2019 |
Anxiety
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Self-report questionnaires were administered to assess quality of life (12-item Kansas City Cardiomyopathy Questionnaire quality of life subscale), level of anxiety (7-item Generalized Anxiety Disorder; GAD-7), level of depression (9-item Patient Health Questionnaire; PHQ-9) and device acceptance (Florida Patient Acceptance Survey; FPAS) to 101 consecutive patients presenting to LVAD clinic.
|
31346241 |
2019 |
Anxiety
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Generalized Anxiety Disorder Scale (GAD-7) is an instrument for the assessment of anxiety.
|
30611061 |
2019 |
Anxiety
|
0.100 |
Biomarker
|
disease |
BEFREE |
There was no correlation between severity of depressive symptoms (as assessed by GDS-30 and BDI) with anxiety and depressive symptoms except for significant correlation between BDI total score and GAD-7 total score (Pearson correlation coefficient-0.319;p = 0.003).Factor analysis of GDS-30 yielded a five factor solution and when the items of other 3 scales were added, the number of factors/symptoms clusters increased to 7.
|
30054249 |
2019 |
Anxiety
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Participants were also screened for depression using the Neurological Disorder Depression Inventory for Epilepsy (NDDI-E) and the Center for Epidemiologic Studies Depression Scale (CES-D) and for anxiety using the Generalized Anxiety Disorder-7 (GAD-7) scale.
|
31181426 |
2019 |
Anxiety
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The anxiety symptomatology was assessed using the GAD-7 questionnaire (cut-off ≥ 10 points).
|
31333520 |
2019 |
Anxiety
|
0.100 |
Biomarker
|
disease |
BEFREE |
Among 200 participants (male, 77.3%; female, 22.8%), 54% had PHQ-9 and 52% had GAD-7 scores indicating moderate to severe depression or anxiety without diagnosis of either disorder.
|
31571840 |
2019 |
Anxiety
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, these data suggest that the loss of GAD67 from SOM neurons may lead to the development of anxiety-like but not depression-like states mediated by modification of Akt/GSK3β activities.
|
31275123 |
2019 |
Anxiety
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Participants with RA completed the Patient Health Questionnaire (PHQ-2, PHQ-9), Patient Reported Outcomes Measurement Information System Depression Short Form-8a (PROMIS Depression) and Anxiety Short Form-8a (PROMIS Anxiety), Hospital Anxiety and Depression Scale anxiety score (HADS-A) and depression score (HADS-D), Overall Anxiety Severity and Impairment Scale (OASIS), Generalized Anxiety Disorder-2 and 7 item scales (GAD-2, GAD-7) and Kessler-6 scale.
|
31199570 |
2019 |